Global Gene Therapy for Blood Disorders Market by Indication
Global Gene Therapy for Blood Disorders Market Based on Mechanism of Action
Global Gene Therapy for Blood Disorders Market Based on Region
Europe
North America
Asia Pacific
Latin America
Middle East & Africa
Chapter 1. Methodology and Scope
1.1. Research Methodology
1.2. Research Scope & Assumptions
Chapter 2. Executive Summary
Chapter 3. Global Gene Therapy for Blood Disorders Market Snapshot
Chapter 4. Global Gene Therapy for Blood Disorders Market Variables, Trends & Scope
4.1. Market Segmentation & Scope
4.2. Drivers
4.3. Challenges
4.4. Trends
4.5. Penetration & Growth Prospect Mapping
4.6. Clinical Trial/Pipeline Analysis
4.7. Industry Analysis – Porter’s Five Forces Analysis
4.8. Competitive Landscape & Market Share Analysis
4.9. Technology Advancement in Gene Therapy for Blood Disorders Market
4.10. Key Trends in the Market
Chapter 5. Market Segmentation 1: Indication Estimates & Trend Analysis
5.1. Indication Type & Market Share, 2024 & 2034
5.2. Market Size (Value US$ Mn) & Forecasts and Trend Analyses, 2021 to 2034 for the following Indication:
5.2.1. Sickle Cell Anemia
5.2.2. β-thalassemia
5.2.3. Hemophilia B
5.2.4. Hemophilia A
Chapter 6. Market Segmentation 1: Mechanism of Action Estimates & Trend Analysis
6.1. Mechanism of Action Type & Market Share, 2024 & 2034
6.2. Market Size (Value US$ Mn) & Forecasts and Trend Analyses, 2021 to 2034 for the following Mechanism of Action:
6.2.1. Gene Therapy
6.2.2. Gene Editing
Chapter 7. Gene Therapy for Blood Disorders Market Segmentation 3: Regional Estimates & Trend Analysis
7.1. North America
7.1.1. North America Gene Therapy for Blood Disorders Market revenue (US$ Million) estimates and forecasts by Indication, 2021-2034
7.1.2. North America Gene Therapy for Blood Disorders Market revenue (US$ Million) estimates and forecasts by Mechanism of Action, 2021-2034
7.1.3. North America Gene Therapy for Blood Disorders Market revenue (US$ Million) estimates and forecasts by country, 2021-2034
7.1.3.1. U.S.
7.1.3.2. Canada
7.2. Europe
7.2.1. Europe Gene Therapy for Blood Disorders Market revenue (US$ Million) by Indication, 2021-2034
7.2.2. Europe Gene Therapy for Blood Disorders Market revenue (US$ Million) by Mechanism of Action, 2021-2034
7.2.3. Europe Gene Therapy for Blood Disorders Market revenue (US$ Million) by country, 2021-2034
7.2.3.1. Germany
7.2.3.2. Poland
7.2.3.3. France
7.2.3.4. Italy
7.2.3.5. Spain
7.2.3.6. UK
7.2.3.7. Rest of Europe
7.3. Asia Pacific
7.3.1. Asia Pacific Gene Therapy for Blood Disorders Market revenue (US$ Million) by Indication, 2021-2034
7.3.2. Asia Pacific Gene Therapy for Blood Disorders Market revenue (US$ Million) by Mechanism of Action, 2021-2034
7.3.3. Asia Pacific Gene Therapy for Blood Disorders Market revenue (US$ Million) by country, 2021-2034
7.3.3.1. China
7.3.3.2. India
7.3.3.3. Japan
7.3.3.4. Australia
7.3.3.5. Rest of Asia Pacific
7.4. Latin America
7.4.1. Latin America Gene Therapy for Blood Disorders Market revenue (US$ Million) by Indication, 2021-2034
7.4.2. Latin America Gene Therapy for Blood Disorders Market revenue (US$ Million) by Mechanism of Action, 2021-2034
7.4.3. Latin America Gene Therapy for Blood Disorders Market revenue (US$ Million) by country, 2021-2034
7.4.3.1. Brazil
7.4.3.2. Rest of Latin America
7.5. MEA
7.5.1. MEA revenue Gene Therapy for Blood Disorders Market revenue (US$ Million) by Indication, 2021-2034
7.5.2. MEA Gene Therapy for Blood Disorders Market revenue (US$ Million) by Mechanism of Action, 2021-2034
7.5.3. MEA Gene Therapy for Blood Disorders Market revenue (US$ Million) by country, 2021-2034
Chapter 8. Competitive Landscape
8.1. Major Mergers and Acquisitions/Strategic Alliances
8.2. Company Profiles
8.2.1. Biomarin Therapeutics
8.2.2. Spark Therapeutics
8.2.3. Shire
8.2.4. bluebird bio, Inc.
8.2.5. CRISPR Therapeutics
8.2.6. Expression Therapeutics LLC
8.2.7. Medgenics
8.2.8. OrphageniX
8.2.9. Freeline Therapeutics
8.2.10. Errant Gene Therapeutics
8.2.11. Sangamo Therapeutics
8.2.12. Sigilon Therapeutics, Inc.
8.2.13. uniQure
8.2.14. Angiocrine Bioscience
8.2.15. Sanofi Genzyme
8.2.16. Other Prominent Players
This study employed a multi-step, mixed-method research approach that integrates:
This approach ensures a balanced and validated understanding of both macro- and micro-level market factors influencing the market.
Secondary research for this study involved the collection, review, and analysis of publicly available and paid data sources to build the initial fact base, understand historical market behaviour, identify data gaps, and refine the hypotheses for primary research.
Secondary data for the market study was gathered from multiple credible sources, including:
These sources were used to compile historical data, market volumes/prices, industry trends, technological developments, and competitive insights.
Primary research was conducted to validate secondary data, understand real-time market dynamics, capture price points and adoption trends, and verify the assumptions used in the market modelling.
Primary interviews for this study involved:
Interviews were conducted via:
Primary insights were incorporated into demand modelling, pricing analysis, technology evaluation, and market share estimation.
All collected data were processed and normalized to ensure consistency and comparability across regions and time frames.
The data validation process included:
This ensured that the dataset used for modelling was clean, robust, and reliable.
The bottom-up approach involved aggregating segment-level data, such as:
This method was primarily used when detailed micro-level market data were available.
The top-down approach used macro-level indicators:
This approach was used for segments where granular data were limited or inconsistent.
To ensure accuracy, a triangulated hybrid model was used. This included:
This multi-angle validation yielded the final market size.
Market forecasts were developed using a combination of time-series modelling, adoption curve analysis, and driver-based forecasting tools.
Given inherent uncertainties, three scenarios were constructed:
Sensitivity testing was conducted on key variables, including pricing, demand elasticity, and regional adoption.